| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S6944 R19614 |
Palmsten (Controls exposed to TCA), 2013 | Preeclampsia and/or eclampsia (ICD-9 codes 642.4x–642.7x, after 140 gestational days and within 30 days after the delivery) | 2nd and/or 3rd trimester | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: No Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) |
0.49 [0.36;0.68] C excluded (control group) |
398/7,143 47/441 | 445 | 7,143 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S6210 R16387 |
Palmsten (Controls unexposed, sick), 2013 | Preeclampsia and/or eclampsia (ICD-9 codes 642.4x–642.7x, after 140 gestational days and within 30 days after the delivery) | 2nd and/or 3rd trimester | retrospective cohort (claims database) | unexposed, sick | Adjustment: Yes Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) Unexposed sick: recent illness/treatment (during or juste before pregnancy or treatment stopped in view of pregnancy) | 1.03 [0.93;1.14] | 398/7,143 3,215/59,219 | 3,613 | 7,143 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S5949 R15264 |
De Vera, 2012 | Pregnancy-induced hypertension (gestational hypertension, pre-eclampsia, or eclampsia after the 20th week of gestation) | during pregnancy (anytime or not specified) | nested case control | unexposed (general population or NOS) | Adjustment: Yes Matched Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) | 1.89 [0.76;4.72] | 6/- 1,210/- | 1,216 | - |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 2 studies | 1.17 [0.72;1.90] | 4,829 | 7,143 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Controls unexposed, sick;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded 6944